Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study

Autor: Anders L. Sørensen, Hans C. Hasselbalch, Mads Emil Bjørn, Claus H. Nielsen, Sabrina Cordua, Vibe Skov, Lasse Kjær, Henrik E. Poulsen, Christina Ellervik

Publikováno v: Redox Biology, Vol 41, Iss , Pp 101895- (2021)

It is unknown if the somatic mutations in chronic myeloproliferative neoplasms (MPNs), JAK2V617F and Calreticulin, are associated with oxidative stress, or impaired mitochondrial defense against reactive oxygen species. In the Danish General Suburban

Externí odkaz: https://doaj.org/article/1661f66dbc9d445e8910fb950af4632b

Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase

Autor: Dres Damgaard, Mads Emil Bjørn, Peter Østrup Jensen, Claus Henrik Nielsen

Publikováno v: Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 32, Iss 1, Pp 1203-1208 (2017)

Protein citrullination catalysed by peptidylarginine deiminase (PAD) may play an important pathogenic role in several chronic inflammatory diseases and malignancies. PAD2, PAD4, and citrullinated proteins are found in the synovium of rheumatoid arthr

Externí odkaz: https://doaj.org/article/2ba3bf1c41194e759be1cc9a3751c9b3

The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms

Autor: Mads Emil Bjørn, Hans Carl Hasselbalch

Publikováno v: Mediators of Inflammation, Vol 2015 (2015)

Reactive oxygen species (ROS) have been implicated in a wide variety of disorders ranging between traumatic, infectious, inflammatory, and malignant diseases. ROS are involved in inflammation-induced oxidative damage to cellular components including

Externí odkaz: https://doaj.org/article/69ad44764b4e47de90f54ba4cbbf9350

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

Autor: Vibe Skov, Anders Lindholm Sørensen, Ole Weis Bjerrum, Christen Lykkegaard Andersen, Mads Thomassen, Christina Ellervik, Niels Pallisgaard, Mads Emil Bjørn, Thomas Stauffer Larsen, Nana Brochmann, Stine Ulrik Mikkelsen, Hans Carl Hasselbalch, Lasse Kjær, Torben A Kruse, Dustin Andersen Patel, Lise Mette Rahbek Gjerdrum, Claus Henrik Nielsen, Hans Torben Mourits-Andersen, Trine Alma Knudsen, Daniel El Fassi

Publikováno v: Sorensen, A L, Mikkelsen, S U, Knudsen, T A, Bjorn, M E, Andersen, C L, Bjerrum, O W, Brochmann, N, Patel, D A, Gjerdrum, L M R, El Fassi, D, Kruse, T A, Larsen, T S, Mourits-Andersen, H T, Nielsen, C H, Ellervik, C, Pallisgaard, N, Thomassen, M, Kjaer, L, Skov, V & Hasselbach, H C 2020, ' Ruxolitinib and interferon-alpha 2 combination therapy for patients with polycythemia vera or myelofibrosis : a phase II study ', Haematologica, vol. 105, no. 9, pp. 2262-2272 . https://doi.org/10.3324/haematol.2019.235648
Haematologica
Sørensen, A L, Mikkelsen, S U, Knudsen, T A, Bjørn, M E, Andersen, C L, Bjerrum, O W, Brochmann, N, Patel, D A, Gjerdrum, L M R, El Fassi, D, Kruse, T A, Larsen, T S, Mourits-Andersen, H T, Nielsen, C H, Ellervik, C, Pallisgaard, N, Thomassen, M, Kjær, L, Skov, V & Hasselbalch, H C 2020, ' Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis : a phase II study ', Haematologica, vol. 105, no. 9, pp. 2262-2272 . https://doi.org/10.3324/haematol.2019.235648

We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-alpha 2 (PEG-IFN alpha 2). The study included 32 patients with polycythemia vera and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2a2689350d3b831d68196ec37176bd6
https://doi.org/10.3324/haematol.2019.235648

The Impact of Somatic Mutations upon the Response to Combination Therapy with Ruxolitinib and Interferon in MPN Patients

Autor: Morten Kranker Larsen, Torben A Kruse, Mads Emil Bjørn, Trine Alma Knudsen, Sarah Friis Christensen, Vibe Skov, Anders Lindholm Sørensen, Mads Thomassen, Hans Carl Hasselbalch, Christina Ellervik, Christina Schjellerup Schjellerup Eickhardt-Dalbøge

Publikováno v: Skov, V, Sørensen, A L, Knudsen, T A, Bjørn, M E, Ellervik, C, Kranker Larsen, M, Eickhardt-Dalbøge, C S S, Christensen, S F, Thomassen, M, Kruse, T A & Hasselbalch, H C 2021, ' The Impact of Somatic Mutations upon the Response to Combination Therapy with Ruxolitinib and Interferon in MPN Patients ', Blood, vol. 138, no. Suppl. 1, 3589 . https://doi.org/10.1182/blood-2021-152154

Introduction: The Philadelphia-negative myeloproliferative neoplasms (MPN) are associated with driver mutations in JAK2, CALR, and MPL genes. Non-driver mutations affect disease progression and treatment response. Combination therapy with pegylated i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96eb24c1af6eba8161549ff12f878679
https://portal.findresearcher.sdu.dk/da/publications/e29403b4-6d57-459f-8f93-f51b5ec6a437